Superior Clinical and Economic Value of IL ‐23 Inhibitors Versus Adalimumab Biosimilars in Plaque Psoriasis

Puntos clave

• The aim is to compare the clinical and economic effectiveness of IL-23 inhibitors to adalimumab biosimilars for treating plaque psoriasis.
• Comparison of clinical benefits between IL-23 inhibitors and adalimumab biosimilars.
• Assessment of cost-effectiveness of different IL-23 inhibitors, particularly guselkumab.
• Evaluation of real-world management strategies for moderate-to-severe psoriasis.
• IL-23 inhibitors demonstrate significant clinical benefits over adalimumab biosimilars.
• Guselkumab is identified as the most cost-effective IL-23 inhibitor.
• Patients experience improved outcomes with IL-23 inhibitors in real-world settings.